Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
P 3 (1)
P 4 (1)

Trial Status

Completed3
Not Yet Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT07096440Not Yet Recruiting

Noninterventional Study on Tolerability and Safety of One Strength Updosing With Novo-Helisen Depot House Dust Mites

NCT03654976Phase 3Completed

Mite Asthma Pediatric Immunotherapy Trial

NCT04100902Phase 4CompletedPrimary

The Effect of Allergen Immunotherapy on Anti-viral Immunity in Patients With Allergic Asthma

NCT03746860Completed

N.I.S of AIT in Adult Patients With House Dust Mite Allergy in Real Practice in France

Showing all 4 trials

Research Network

Activity Timeline